Vyleesi® product results: 14% growth in prescriptions dispensed over prior quarter – 6 consecutive quarters of double digit growth.
Click here to learn more ›

November 2020

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update

– Regained North American Rights to Vyleesi® for HSDD with Palatin Receiving $12 Million from AMAG Plus $4.3 Million Due March 31, 2021 – Phase 2 Clinical Results of PL9643 for the Treatment of Dry Eye Disease on Track for December 2020 – $86.6 Million in Cash and Cash Equivalents as of September 30, 2020 …

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update Read More »

Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020

Nov 12, 2020, 07:30 ET CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive …

Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020 Read More »

Scroll to Top